Industry
Biotechnology
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Loading...
Open
2.36
Mkt cap
97M
Volume
126K
High
2.40
P/E Ratio
4.67
52-wk high
3.67
Low
2.27
Div yield
N/A
52-wk low
1.85
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 1:54 pm
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 10:13 am
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 3:41 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Insights
June 12, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 11:21 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 11:13 am
Portfolio Pulse from Avi Kapoor
February 02, 2024 | 1:21 pm
Portfolio Pulse from Charles Gross
January 23, 2024 | 9:51 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.